Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension

What Was Tested

This randomized controlled trial paper looks at Exenatide.

Cognitive function can be affected in conditions with raised intracranial pressure (ICP) such as idiopathic intracranial hypertension (IIH).

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, women only.

Women with IIH and telemetric ICP monitors (n = 15) were treated with exenatide (n = 7) or placebo (n = 8) for 12 weeks.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

A time span of 12 weeks appears in the methods.

This was an exploratory study of the IIH:Pressure trial (ISTCRN 12678718).

Cognitive function was tested using the National Institute of Health Toolbox Cognitive Battery at baseline and 12 weeks.

What Was Measured

Topics PubMed links to this paper include Exenatide, Pseudotumor Cerebri, Cognition, Intracranial Pressure, Peptides, Venoms and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide over 12 weeks.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Eye (London, England)), a journal based in England.

More context: the Exenatide compound page, all human trials.